Drug interactions
Larotrectinib + Tofacitinib
Severity: Minor
Larotrectinib and Tofacitinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate with weak inhibitory potential and may slightly increase tofacitinib exposure. Any clinical effect is expected to be small.
What this interaction means in plain words
Larotrectinib and Tofacitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Tofacitinib belongs to Musculoskeletal.
Why it happens
Possible weak CYP3A4 inhibition by larotrectinib reducing tofacitinib clearance.
What to do
No dose change is usually required. Monitor for tofacitinib adverse effects.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Tofacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Tofacitinib
- Baricitinib + Tofacitinib Contraindicated
- Cladribine + Tofacitinib Contraindicated
- Tofacitinib + Upadacitinib Contraindicated
- Abatacept + Tofacitinib Major
- Anti-thymocyte + Tofacitinib Major
- Antithymocyte globulin equine + Tofacitinib Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Tofacitinib?
MediHelp rates the interaction as minor. Larotrectinib and Tofacitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate with weak inhibitory potential and may slightly increase tofacitinib exposure. Any clinical effect is expected to be small.
How serious is the interaction between Larotrectinib and Tofacitinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is usually required. Monitor for tofacitinib adverse effects.
What other medicines interact with Tofacitinib?
MediHelp also lists interactions of Tofacitinib with, for example, Baricitinib, Cladribine, Upadacitinib. The full list is on the Tofacitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
